Scientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.
Chronic pain patients with legal access to medicinal cannabis significantly decrease their use of opioids, according to data published online ahead of print in The Journal of Pain. “Among study participants, medical cannabis use was associated with a 64% decrease in opioid use, decreased number and side effects of medications, and an improved quality of life,” investigators concluded.
The long-term, daily use of cannabis is associated with improved analgesia and reduced opioid use in patients with treatment-resistant chronic pain conditions, according to clinical trial data reported online ahead of print in The Clinical Journal of Pain.
Cannabinoids are safe and effective in the treatment of chronic pain conditions, according to a review of recent clinical trials published online ahead of print in the Canadian Journal of Anesthesia. They concluded, “Overall, the recent literature supports the idea that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain and possibly cancer-related pain.”
Cannabinoids are safe and effective for the treatment of chronic pain, according to the results of a systematic review of randomized controlled trials published in the Journal of Neuroimmune Pharmacology. Authors concluded, “The current systematic review provides further support that cannabinoids are safe, demonstrate a modest analgesic effect and provide a reasonable treatment option for treatment chronic non-cancer pain.”
Chronic pain patients who use herbal cannabis daily for one-year report reduced discomfort and increased quality of life compared to controls, and do not experience an increased risk of serious side effects, according to clinical data published online ahead of print in the Journal of Pain. Researchers at McGill University in Montreal assessed the long-term health of 216 medicinal cannabis users with chronic non-cancer pain who consumed a daily standardized dose (12.5 percent THC) of herbal cannabis compared to 215 controls (chronic pain suffers who did not use cannabis). Subjects […]
NORML is pleased to present the latest expanded/updated edition of the publication Emerging Clinical Applications for Cannabis & Cannabinoids — a comprehensive review of the latest peer-reviewed science specific to the safety and therapeutic efficacy of whole-plant cannabis and/or its components.
States that permit qualified patients to access medical marijuana via dispensaries possess lower rates of opioid addiction and overdose deaths, according to a study published by the National Bureau of Economic Research, a non-partisan think-tank. “[S]tates permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not,” authors reported. They found that women over the age of 40 showed the most significant decrease in problematic opioid use.
Vaporized cannabis mitigates pain intensity in diabetic subjects in dose-dependent manner, according to clinical trial data published online ahead of print in The Journal of Pain. Authors reported: “This small, short-term, placebo-controlled trial of inhaled cannabis demonstrated a dose-dependent reduction in diabetic peripheral neuropathy pain in patients with treatment-refractory pain. … Overall, our finding of an analgesic effect of cannabis is consistent with other trials of cannabis in diverse neuropathic pain syndromes.”